IE
STLN

Israel Englander’s Starling Oncology STLN Stock Holding History

Israel Englander’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$526K Sell
96,875
-34,647
-26% -$146K ﹤0.01% 4749
2026
Q1 		$404K Sell
131,522
-61,619
-32% -$189K ﹤0.01% 4871
2025
Q4 		$688K Sell
193,141
-757,860
-80% -$2.81M ﹤0.01% 4741
2025
Q3 		$3.32M Buy
951,001
+545,992
+135% +$1.87M ﹤0.01% 3546
2025
Q2 		$830K Buy
+405,009
New +$1.01M ﹤0.01% 4550
2024
Q3 		– Sell
-109,207
Closed -$50.2K – 6483
2024
Q2 		$50.2K Sell
109,207
-39,057
-26% -$33.3K ﹤0.01% 5415
2024
Q1 		$234K Sell
148,264
-27,148
-15% -$51.6K ﹤0.01% 5289
2023
Q4 		$358K Buy
175,412
+78,090
+80% +$135K ﹤0.01% 4852
2023
Q3 		$136K Sell
97,322
-105,356
-52% -$109K ﹤0.01% 5252
2023
Q2 		$112K Buy
+202,678
New +$107K ﹤0.01% 5302
2022
Q3 		– Sell
-121,145
Closed -$613K – 7499
2022
Q2 		$613K Sell
121,145
-38,678
-24% -$282K ﹤0.01% 4791
2022
Q1 		$1.14M Buy
+159,823
New +$1.08M ﹤0.01% 4405
2021
Q4 		– Sell
-1,582,630
Closed -$15.7M – 7382
2021
Q3 		$15.7M Buy
1,582,630
+83,190
+6% +$826K 0.01% 1555
2021
Q2 		$14.9M Buy
1,499,440
+7,415
+0.5% +$74.6K 0.01% 1483
2021
Q1 		$14.9M Sell
1,492,025
-84,575
-5% -$901K 0.01% 1365
2020
Q4 		$17M Hold
1,576,600
– – 0.01% 1206
2020
Q3 		$16.4K Buy
1,576,600
+1,466,800
+1,336% +$15.2M 0.02% 909
2020
Q2 		$1.1M Buy
+109,800
New +$1.09M ﹤0.01% 2933

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Israel Englander's STLN Position: Q2 2026 in Review

Israel Englander reduced its Starling Oncology (STLN) stake by 26% in Q2 2026, selling an estimated $146K and leaving 96,875 shares worth $526K. The position accounts for ﹤0.01% of the portfolio, ranked #4749.

Israel Englander first reported a position in STLN in Q2 2020 and has held it in 18 quarters since. The position peaked at $17M in Q4 2020. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Israel Englander held 96,875 shares of Starling Oncology worth $526K as of Q2 2026.
  • Israel Englander sold 34,647 Starling Oncology shares in Q2 2026, an estimated $146K.
  • Starling Oncology made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4749 holding.
  • Israel Englander first reported a position in Starling Oncology in Q2 2020 and has held it in 18 quarters since.
  • Israel Englander's Starling Oncology position peaked at $17M in Q4 2020.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.